Skip to content
Nanograb logo

Nanograb

Nanograb is a YC Summer 2023 (S23) company. Based in San Francisco, CA, USA. Team of 5.

  • AI-powered Drug Discovery
  • Nanomedicine
  • Biotech
  • Drug Delivery
  • Therapeutics

About Nanograb

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Nanograb develops AI-generated molecular binders that direct gene therapies and other drugs to specific cell types in the body. The platform identifies optimal binder combinations for a given disease target, replacing the slow, manual process of experimentally screening delivery molecules. Biotech and pharmaceutical teams use it to build cell-type-precise therapies that conventional delivery methods cannot achieve.

From the Y Combinator listing

How Nanograb describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

AI-generated binders for targeted drug delivery

Nanograb is a computational drug discovery company that uses AI to generate the best combination of binders to treat different diseases. Our product allows drugs to be targeted to very specific areas of the body.

Facts

Industry
Healthcare / Healthcare -> Drug Discovery and Delivery
Location
San Francisco, CA, USA
Team size
5
Status
Active
Stage
Early

Founders (3)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works